Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label active-controlled multicenter study of semaglutide injection for obesity without diabetes
CTR20244492Phase 3Completed
- Sponsor
- Sinopep-Allsino Biopharmaceutical
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Sinopep-Allsino Biopharmaceutical. Primary endpoint: Percent change in body weight from baseline after 44 weeks of treatment. Started Dec 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20244492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244492.